Britain and America have finalized a major bilateral deal that will ensure zero levies on British medicine exports being sold in the US market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has committed to increase spending on pharmaceuticals through the National Health Service (NHS). This move secures that import taxes on these crucial goods will be held at zero for a duration of 36 months.
This deal is in response to previous statements to significantly raise import taxes on branded drug products, with increases mentioned up to double the cost.
"This arrangement between the United Kingdom strengthens the worldwide climate for innovative medicines and introduces much-needed balance to transatlantic drug exports," a statement declared.
Trade Importance
Medicines constitute one of the Britain's biggest goods shipped to the United States, which is by far the largest destination for major UK drugmakers.
Export figures reveal that in the 12 months leading up to the third quarter, the UK exported drugs worth £11.1bn to the US. This amount accounted for 17.4% of all goods exports in that span.
"This deal protects jobs, stimulates capital expenditure and facilitates the UK to emerge as a international leader for medical research," a government official commented.
Detailed British Pledges
The agreement involves several key changes from the British government:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it deems new medicines to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a goal to raise overall health service expenditure on drugs from 0.3% of GDP to 0.6% over the next decade.
- Refund Ceiling: The percentage pharmaceutical firms must refund to the NHS to stay within budget will be capped at 15%. In the past, repayments were more than 20%.
Broader Context
This agreement comes amid a long-running row between the pharmaceutical industry and the British authorities over drug pricing and regulatory access.
This friction were exacerbated by claims that US patients were paying several times more for the equivalent treatments than people in the UK and Europe.
Over the last 18 months, several large drug company projects in the UK have been delayed or abandoned, while substantial investments have been announced toward projects in the United States.
One official publicly accepted that the NHS needed to increase expenditure on treatments, noting that its expenditure on drugs had decreased as a percentage of its resources over the previous ten-year period.
